NTRA stock climbs after an analyst raises the price target and the company announces a new partnership for its colon cancer test.
Natera (NTRA) shares reached a record high Monday following an analyst’s price target increase and new partnership news. The stock surged after the company reported positive developments for its colon cancer test, pushing it into a buy zone within a cup base pattern.
Prior to this, Natera had experienced a strong breakout last week on the back of the cancer test announcement. The stock’s three-year chart shows constructive action, reinforcing investor confidence in its growth trajectory.
The market reaction drove NTRA to new highs, reflecting optimism about the company’s diagnostic advancements and expanded market opportunities.